Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Danielle Enserro
Blood-based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG-GY012
CONFLICT OF INTEREST STATEMENT Andrew B. Nixon reports research funding from Genentech, MedImmune/AstraZeneca, Seattle Genetics and GenMab; and consulting fees from GSK, Leap Therapeutics, and Promega Corporation. Danielle M. Enserro reports Cooperative Group/NCTN grant funding for all aspects of this trial including travel to group meetings; statistical support; study monitoring; etc. Jesus Gonzalez Bosquet reports patent application #63/428,346 (Methods for detecting and treating ovarian cancer).
Improving the Estimation of Prediction Increment Measures in Logistic and Survival Analysis
Font Type: Arial Georgia Verdana Font Size: Aa Aa Aa Line Spacing: Column Width: This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessArticle by Danielle M. Enserro SciProfiles Scilit Preprints.org Google Scholar Dr. Danielle M. Enserro is the Associate Director of Biostatistics in the Clinical Trials Division & [...] Dr. Danielle M.
NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
CONFLICT OF INTEREST STATEMENT Danielle Enserro has disclosed that Cooperative Group/NCI National Clinical Trials Network grant funding was received for all aspects of this trial including travel to group meetings, statistical analysis, study monitoring, etc. Mark Borowsky reports that he serves on the Advisory Board for both AstraZeneca and GlaxoSmithKline.
Temporal Trends in the Remaining Lifetime Risk of Cardiovascular Disease Among Middle-Aged Adults Across 6 Decades: The Framingham Study
Originally published18 Apr 2022https://doi.org/10.1161/CIRCULATIONAHA.121.057889Circulation. 2022;0 Abstract Background: The remaining lifetime risk (RLR) is the probability of developing an outcome over the remainder of one's lifespan at any given age.
Clinical Course after a First Episode of Heart Failure: Insights from the Framingham Heart Study
Research Article Ramachandran S. Vasan MD Corresponding Author E-mail address: vasan@bu.edu Framingham Heart Study, Framingham, MA Preventive Medicine and Cardiology Sections, Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, Boston University, Boston, MA Corresponding author Ramachandran S. Vasan, MD, Framingham Heart Study, 73 Mount Wayte Ave, Framingham, MA 01702–5803, Tel:508‐935‐3450, Fax: 508‐626‐1262.
Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer
Figure 1. Study Schema After the maximum tolerated dose was estimated, the expansion cohort started treatment. GOG indicates Gynecology Oncology Group; HDR, high dose rate brachytherapy; and LDR, low dose rate brachytherapy. Figure 2. Gynecology Oncology Group 9929 Study CONSORT Diagram DLT indicates dose-limiting toxic effects; CRT, chemoradiotherapy. Figure 3. Progression-Free and Overall Survival in Patients Receiving 2 or More Cycles of Ipilimumab Figure 4.
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
During 2019, the American Cancer Society estimates that approximately 22,530 women will be diagnosed with ovarian carcinoma, and approximately 13,980 patients will die as a result of the disease.1 The prevalence is approximately 10 times its incidence, with nearly 200,000 women in the United States living with the disease at any given time.
Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study
Background Fibroblast growth factor 23 (FGF23) is emerging as a novel biomarker of bone metabolism, chronic kidney disease, and cardiovascular disease (CVD). However, its clinical correlates and potential predictive role in a community‐based setting are incompletely understood.
Association of Ideal Cardiovascular Health With Vascular Brain Injury and Incident Dementia
Methods—Our aim was to investigate the prospective association of ideal CVH with vascular brain injury, including the 10-year risks of incident stroke and dementia, as well as cognitive decline and brain atrophy on magnetic resonance imaging, measured for ≈7 years. We studied 2750 stroke- and dementia-free Framingham Heart Study Offspring cohort participants (mean age, 62±9 years; 45% men).
Association of Exhaled Carbon Monoxide With Stroke Incidence and Subclinical Vascular Brain Injury
Background and Purpose—Exhaled carbon monoxide (CO) is associated with cardiometabolic traits, subclinical atherosclerosis, and cardiovascular disease, but its specific relations with stroke are unexplored. We related exhaled CO to magnetic resonance imaging measures of subclinical cerebrovascular disease cross-sectionally and to incident stroke/transient ischemic attack prospectively in the Framingham Offspring study.
Residual Cardiovascular Risk in Individuals on Blood Pressure-Lowering Treatment
Background Hypertensive individuals on blood pressure (BP)–lowering treatment with BP in the normal or high‐normal range have higher cardiovascular risk than untreated persons with usual BP in the same range. This residual risk (relative and absolute) is not well quantified and may be attributable in part to the higher burden of subclinical disease in treated individuals.
Implications of the US Cholesterol Guidelines on Eligibility for Statin Therapy in the Community: Comparison of Observed and Predicted Risks in the Framingham Heart Study Offspring Cohort
Background Concerns have been raised that the 2013 atherosclerotic cardiovascular disease (ASCVD) risk estimator overpredicts risk in contemporary cohorts. Whether suboptimal calibration will lead to overtreatment with statins is unknown.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Danielle
Contact Danielle, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack